ライフサイエンスコーパス: event-free survival rate

1 The primary end point was the five-year event-free survival rate.

2 a result, had a significantly lower cardiac event-free survival rate.

3 P5 expression displayed inferior overall and event-free survival rates.

4 utcomes compared with White patients (5-year event-free survival rate, 25% [95% CI, 9%-67%] compared

5 ry cohort examined (combined cohorts: 5-year event-free survival rates, 43.3% vs 68.5%; hazard ratio

6 Despite this result, the 3-year event-free survival rate (52.9% [44.6% to 62.8%] for Clo

7 ripheral-blood alpha-L-iduronidase activity (event-free survival rate, 85 percent).

8 therapy, there were no differences in 5-year event-free survival rates according to ACS10 score (low

9 Currently, the event-free survival rate after allogeneic-matched siblin

10 ative coronary stenting resulted in a higher event-free survival rate and a lower probability of repe

11 The 5-year event-free survival rate and risk of relapse in obese ve

12 was universally fatal, but current long-term event-free survival rates are nearly 80%.

13 The projected event-free survival rate at 24 months is 88%, and all pa

14 The event-free survival rate at 6-month follow-up was 91% in

15 The cardiac event-free survival rates at 1, 2 and 3 years were 99.2%

16 Event-free survival rates at 3 years in patients without

17 event-free survival rates at 5 years in 892 patients who

18 gap in prognosis was abolished in study XV: event-free survival rates at 5 years were 86.4% +/- 5.2%

19 In patients who responded adequately, event-free survival rates at 5 years were 90.1% (95% CI

20 Over the 8-year follow-up, cardiovascular event-free survival rates based on CRP levels above or b

21 erences in outcome according to race (5-year event-free survival rate, Black patients, 50% [95% CI, 3

22 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

23 CS10 scores had a significantly worse 5-year event-free survival rate compared with those with high s

24 oid leukemia (AML) have significantly higher event-free survival rates compared to those with non-DS

25 val rate was 86.7% at 5 years, with a 5-year event-free survival rate decreasing progressively to 50.

26 The main study endpoint was the event-free survival rate defined as freedom from target

27 ninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in te

28 The long-term event-free survival rate for patients with high-grade FN

29 The primary outcome was one-year event-free survival rate for the combined end point of d

30 The 72-month event-free survival rate for the composite end point of

31 The 3-year event-free survival rate for these patients was 58%.

32 Event-free survival rates for cardiovascular events were

33 With current treatment regimens, event-free survival rates for childhood acute lymphoblas

34 The 5-year estimated abandonment-sensitive event-free survival rates for patients undergoing upfron

35 The 5-year event-free survival rates for patients with stages 0 to

36 The estimated 5-year overall survival and event-free survival rates for the entire group were 80%

37 The 5-year event-free survival rate (freedom from death, myocardial

38 As the overall long-term event-free survival rate in children with acute lymphobl

39 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

40 Event-free survival rates in noninducible and inducible

41 subtypes continue to have poor outcomes with event free survival rates <40% despite the use of high i

42 onserving strategies at 20 years, the breast event-free survival rate (no invasive cancer or DCIS) wa

43 No improvements in event-free survival rates occurred with successive coope

44 atients remained relapse free, with a 2-year event-free survival rate of 50% +/- 8%.

45 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

46 tained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval

47 te a 98% overall survival rate and a 6-month event-free survival rate of 78% (six target vessel revas

48 At 1 year, survival was 98%, with an event-free survival rate of 80%, reflecting predominantl

49 was 90.9% (95% CI, 83.9% to 95.0%), with an event-free survival rate of 87.8% (95% CI, 81.1% to 92.4

50 e primary objective was maintaining a 5-year event-free survival rate of 90% in patients with an adeq

51 ering an overall survival rate of 95% and an event-free survival rate of 92%), and encouraging outcom

52 s classified as HER2DX low risk had a 6-year event-free survival rate of 93.6% (95% CI 92.0-95.2), co

53 ars are 88%, 88%, and 77%, with an estimated event-free survival rate of only 30% at 15 years.

54 steosarcoma has a poor prognosis with a 2-y, event-free survival rate of ~15 to 20%, highlighting the

55 rcent, respectively (P<0.001), and five-year event-free survival rates of 56 percent and 44 percent (

56 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

57 s with 0, 1, or 2 adverse factors had 2-year event-free survival rates of 78%, 49%, and 20% (P < .001

58 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

59 temporary treatments have resulted in 5-year event-free survival rates of approximately 80% for child

60 The significantly higher event-free survival rates of Down syndrome (DS) children

61 The high event-free survival rates of Down syndrome (DS) children

62 evel in children with ALL, securing a higher event-free survival rate overall.

63 The estimated 5-year event-free survival rate (+/- SE) for patients with TEL

64 emia (ALL), dexamethasone resulted in higher event-free survival rates than prednisone, presumably du

65 The mean (+/-SE) event-free survival rate three years after the first ran

66 The event-free survival rate three years after the second ra

67 The event-free survival rate to hospital discharge was 90%.

68 , over a median of 3 years of follow-up, the event-free survival rate was 100%, and no patients recei

69 The event-free survival rate was 61%, 54% and 47% at one, tw

70 The event-free survival rate was 65.8% in the SES group and

71 For patients with PM, 5-year event-free survival rate was 73% (95% CI, 68% to 79%), a

72 ted 3-year overall survival rate was 91% and event-free survival rate was 77%.

73 The event-free survival rate was 80 +/- 1.5% at 1 year, 71 +

74 2-year event-free survival rate was 81% (95% CI 64-90).

75 rall survival rate was 93.3% +/- 7%, and the event-free survival rate was 86.7% +/- 9.5% for the obse

76 During a median of 5 years of follow-up, the event-free survival rate was 93%, and the overall surviv

77 After 3 years, the event-free survival rate was 94% (95% confidence interva

78 , and 50.0%, respectively; observed 24-month event-free survival rates were 36.1%, 20.0%, and 20.0%,

79 went transplantation, the 3-year overall and event-free survival rates were 52.5% and 44.2%, respecti

80 Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%.

81 The 1 year overall and event-free survival rates were 60% and 32%, respectively

82 actuarial survival, response, and actuarial event-free survival rates were 62%, 48%, and 27%, respec

83 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

84 The 6- and 12-month event-free survival rates were 75% (95% CI, 41%-91%) and

85 The 1- and 2-year cumulative event-free survival rates were 87% and 81%.

86 Two-year event-free survival rates were 97% in the ATRA-arsenic t

87 splant-related mortality (TRM), relapse, and event-free survival rates were analyzed.

88 Remission induction, survival, and event-free survival rates were not significantly differe

89 t years have not translated into an improved event-free survival rate, which continues to be influenc

90 Better event-free survival rates with second-generation TKI the